This paper describes the authors’
preliminary studies directed
toward the possibility of the practical implementation of the idea
to design efficient antitumor drugs based on hybrid molecules composed
of fullerene C60 and quadricyclanes. The essence of the
proposed idea is that these hybrid molecules are able to cleave DNA
owing to the fullerene moiety they contain and to simultaneously thermally
affect tumor cells via cleavage of the carbon–carbon bond in
quadricyclanes under the action of Pd and Pt ions. As a result, testing
of the cytotoxic activity in vitro for a number of fullerene C60 hybrids with the norbornadiene or quadricyclane moieties
against the human T-lymphoblastic leukemia cells (Jurkat cells) in
combination of the known cisplatin drug, which was taken as the source
of Pt ions, showed a statistically reliable dose-dependent increase
in the number of dead cells in each group, which were formed according
to the amount of cisplatin added, in comparison with the control,
that is, cells treated with cisplatin or quadricyclane fullerene derivatives
alone. Indeed, the difference between the percentages of viable cells
after treatment with either cisplatin alone or cisplatin in combination
with methanofullerene 5 ranged from ∼10% (for
Pt (0.015 mkM), 5 (0.015 mkM)) to ∼55% (for Pt
(0.03 mkM), 5 (0.045 mkM)).